Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -2.00% and Operating profit at -41.16% over the last 5 years
2
With a fall in Net Sales of -21.4%, the company declared Very Negative results in Mar 25
3
With ROE of 2.90%, it has a expensive valuation with a 4.52 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,859 Million (Mid Cap)
156.00
NA
0.00%
-0.16
2.90%
4.52
Revenue and Profits:
Net Sales:
160 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.33%
0%
27.33%
6 Months
80.94%
0%
80.94%
1 Year
113.39%
0%
113.39%
2 Years
33.4%
0%
33.4%
3 Years
117.79%
0%
117.79%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Guangdong Taienkang Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.00%
EBIT Growth (5y)
-41.16%
EBIT to Interest (avg)
28.35
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.35
Tax Ratio
4.49%
Dividend Payout Ratio
78.28%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.79%
ROE (avg)
7.23%
Valuation key factors
Factor
Value
P/E Ratio
156
Industry P/E
Price to Book Value
4.52
EV to EBIT
232.81
EV to EBITDA
78.22
EV to Capital Employed
5.16
EV to Sales
11.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.22%
ROE (Latest)
2.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
160.20
203.80
-21.39%
Operating Profit (PBDIT) excl Other Income
6.00
57.40
-89.55%
Interest
2.50
2.20
13.64%
Exceptional Items
-0.30
-1.30
76.92%
Consolidate Net Profit
1.20
36.20
-96.69%
Operating Profit Margin (Excl OI)
-66.90%
222.10%
-28.90%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -21.39% vs -2.53% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -96.69% vs -34.77% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
711.30
751.00
-5.29%
Operating Profit (PBDIT) excl Other Income
158.50
218.50
-27.46%
Interest
8.80
1.80
388.89%
Exceptional Items
0.10
-6.70
101.49%
Consolidate Net Profit
97.00
153.50
-36.81%
Operating Profit Margin (Excl OI)
145.50%
238.20%
-9.27%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -5.29% vs -3.18% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -36.81% vs -12.08% in Dec 2023
About Guangdong Taienkang Pharmaceutical Co., Ltd. 
Guangdong Taienkang Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






